-
公开(公告)号：EP3630177A1
公开(公告)日：2020-04-08
申请号：EP18728153.0
申请日：2018-05-30
申请人： MorphoSys AG
IPC分类号： A61K39/395 , A61K31/00 , C07K16/28 , A61P35/00
-
公开(公告)号：EP4268900A3
公开(公告)日：2024-03-06
申请号：EP23190328.7
申请日：2018-05-30
申请人： MorphoSys AG
IPC分类号： A61K39/395 , A61K31/00 , C07K16/28 , A61P35/00
摘要： The present disclosure provides anti-CD19 antibodies and venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma. The anti-CD19 antibodies, in particular MOR00208, and venetoclax are administered to patients suffering non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.
-
公开(公告)号：EP4268900A2
公开(公告)日：2023-11-01
申请号：EP23190328.7
申请日：2018-05-30
申请人： MorphoSys AG
IPC分类号： A61P35/00
摘要： The present disclosure provides anti-CD19 antibodies and venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma. The anti-CD19 antibodies, in particular MOR00208, and venetoclax are administered to patients suffering non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.
-
-
搜索结果
3 条记录 (耗时 0.007 秒)
